The biotech sector in 2025 presents a landscape brimming with both opportunities and challenges. The industry is being shaped ...

DNLI has had a good run in the past year on positive pipeline updates. A potential approval of its Hunter Syndrome drug should be a boost. However, recent pipeline setbacks warrant caution.